AzTrials
AzTrials

Idiopathic HypersomniaSL-HIPNCT06153615

Local Sleep in Idiopathic Hypersomnia

A study testing EEG (64 electrodes), Cognitive task (SART) and Pupillometry and eye tracking in people with Idiopathic Hypersomnia, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Idiopathic hypersomnia (IH) is a rare and poorly studied disease characterized by excessive daytime sleepiness different from that of narcolepsy (sleep drunkness non-recuperative naps and nocturnal blackout). Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Idiopathic Hypersomnia
What is being tested?
EEG (64 electrodes), Cognitive task (SART) and Pupillometry and eye tracking
Could I receive a placebo?
No, everyone receives an active treatment
How many people
63 participants
Where
1 siteFrance
Study dates
2 Feb 2024to 29 Apr 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Healthy subjects and people with IH and NT1:
  • ->18 years old, of both sexes, without legal protection.
  • Affiliated to the French social security system
  • Signature of free and informed consent
  • Fluency in spoken and written French
  • Specific to people with IH:
Show all 9Show fewer
  • -Diagnosis of IH according to the ICSD-3, already made in the sleep pathology department of the Pitié after a specialized medical interview and a standardized 48h assessment (Night 1+TILE+Night 2+two naps): Sleep time > 660 min or TILE latency <8 min, <2 SOREMPs.
  • Specific to people with NT1:
  • Diagnosis of narcolepsy type 1 according to the ICSD-3, already made in the sleep pathology department of the Pitié after a specialized medical interview and a standardized 48h workup (Night 1+TILE+Night 2+two naps) and sometimes a lumbar puncture: hypocretin <110 pmol/L in CSF or cataplexy and TILE latency <8 min, >1 SOREMP.

Who cannot join

  • Shift or night work
  • Sleep debt on the day of the recording (questioning and sleep diary one week before the recording)
  • Other sleep pathology causing daytime sleepiness (sleep apnea, insomnia, parasomnia for example)
  • Cerebral neurological pathology
  • Depressive episode
  • Any psychotropic treatment modifying the EEG structure
  • Failure to wean from arousing treatment on the day of the test.
  • Inability to travel by transport or to be transported by a relative on the day of the recording.

Trial locations and contacts

1 site in 1 country.

France1 site
  • Pitié Salpêtrière

    Paris

Other trials in France

About this study

Official title: Sleeping With Open Eyes: Local Sleep in Idiopathic Hypersomnia

Idiopathic hypersomnia (IH) is a rare and poorly studied disease characterized by excessive daytime sleepiness different from that of narcolepsy (sleep drunkness non-recuperative naps and nocturnal blackout). Local sleep is a recent concept, proposing a local regulation of the sleep-wake state, characterized by slow waves (SW) restricted to certain regions of a globally awake brain. The investigators are going to investigate whether local sleep could explain the sleepiness of these patients better than the global occurrence of sleep which are not very frequent during daytime tests in IH.

The investigators propose to look for local sleep through the detection of local slow waves in the EEG of resting wakefulness and during an attentional task in people with IH compared to people with NT1 (sleepy, but with a different type of sleepiness from IH, more abrupt and including REM sleep) and non sleepy people.

Read the detailed description

Local sleep is a recent concept, suggesting a local regulation of the sleep-wake state, characterized for example in wakefulness by slow waves restricted to certain regions of a globally awake brain, correlating with modifications of mental experience and behavior. Although the phenomenon of local sleep has been demonstrated following acute sleep deprivation, its importance in explaining attentional fluctuations during a normal day is only beginning to be investigated. Moreover, inter-individual variations remain unexplored. The investigators propose to study in EEG (64 electrodes) the occurrence of local sleep in different states of sleepiness, in particular in idiopathic hypersomnia (IH) in comparison to that of narcolepsy type 1 (NT1) and to non-drowsy individuals, both in the resting state and during a sustained attention test (SART). This study will provide a better understanding of intra- (over the course of a day) and inter-individual fluctuations in the local sleep phenomenon potentially involved in this disease and its impact on cognition.

Anticipated number of participants:

60 including:

  • 20 people with idiopathic hypersomnia
  • 20 people with type 1 narcolepsy
  • 23 people with no previous history

Practical procedure:

Single visit: presence from 9:30 am to 3:30 pm

  • General questionnaire on sleep habits and symptoms.
  • Equipment: EEG 32 electrodes, EOG, ECG, eye tracker and thoracoabdominal belts.
  • Morning and afternoon recording: 10 minutes in resting state, 60 minutes of digital SART (go-no-go test in front of a screen, with intermittent evaluation of mental state), then 10 minutes of rest.
Being tested
EEG (64 electrodes), Cognitive task (SART), Pupillometry and eye tracking, Thoracoabdominal belts
Keywords
Idiopathic Hypersomnia, Narcolepsia type 1
Medical subject headings
Idiopathic Hypersomnia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • EEG (64 electrodes)Other

    EEG recording while awake, at rest then during an attentional cognitive test

  • Cognitive task (SART)Other

    Sustained attention go-no-go task (press a button each time a number is presented on a screen (1/second) except when the 3 appears) Assessment of mental status approximately every 45 seconds (task focus, mind wandering, mental blank, and sleepiness status)

  • Pupillometry and eye trackingOther

    Study of pupil size and gaze path during the cognitive test (correlated with alertness)

  • Thoracoabdominal beltsOther

    Abdominal and thoracic belts (used in all nocturnal polysomnographic recordings) for respiratory movement studies (correlated with sleepiness)

Study groups in NCT06153615
Study groupRoleWhat they receive
Idiopathic HypersomniaExperimentalNot described
Receives: Other: EEG (64 electrodes); Other: Cognitive task (SART); Other: Pupillometry and eye tracking; Other: Thoracoabdominal belts
Narcolepsy type 1Active comparatorNot described
Receives: Other: EEG (64 electrodes); Other: Cognitive task (SART); Other: Pupillometry and eye tracking; Other: Thoracoabdominal belts
Healthy subjectActive comparatorNot described
Receives: Other: EEG (64 electrodes); Other: Cognitive task (SART); Other: Pupillometry and eye tracking; Other: Thoracoabdominal belts

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. local sleep topography

    Density and topography of local sleep through the detection of local slow waves (SW) during resting wakefulness and during a daytime attentional test in IH, narcolepsy and healthy subjects

    Measured: At enrollment visit

Secondary outcomes (3)
  1. Daytime dynamics of local sleep

    Density and topography of local sleep through the detection of local slow waves at two times of the day.

    Measured: At enrollment visit

  2. behavioral implications of local sleep

    Correlation of slow wave characteristics to mental experience and performance (reaction time, omission, impulsivity) during the sustained attention task.

    Measured: At enrollment visit

  3. correlation between local sleep and behavioral marker of alertness

    Correlation of pupillometric and eye tracking measurements, respiratory and heart rate parameters (assessments correlated to the state of alertness) to the different measured parameters

    Measured: At enrollment visit

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Dec 2023
  2. Study start2 Feb 2024
  3. Primary completion29 Apr 2026
  4. Study completion29 Apr 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Health services research
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
63 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06153615
Sponsor's protocol ID
APHP230749
Other IDs
IDRCB 2023-A01145-40
Acronym
SL-HIP
Status last verified
Sep 2026
First submitted
29 Sep 2023
Last updated
11 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: The data will be confidential until their publication in a peer reviewed journal. Sharing will be feasible after, in case of reasonable request to the PI.

Questions about this trial

What is this clinical trial studying?

A study testing EEG (64 electrodes), Cognitive task (SART) and Pupillometry and eye tracking in people with Idiopathic Hypersomnia, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 11 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

local sleep topography (time frame: At enrollment visit). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Sep 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in